Foamix to release results of Phase 2 FMX103 trial

Foam Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of topical foams to fill unmet dermatology needs, will be releasing the results of its Phase 2 FMX103 clinical trial on Sept. 12.

The study was developed to find a treatment for papulopustular rosacea, a chronic skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead.

The Phase 2 trial was conducted on 233 patients in 18 facilities across Germany. It was double-blind, randomized and placebo-controlled. During the 12-week span, patients randomly received either a high dose of FMX103, a low dose of FMX103 or a vehicle foam. The treatment cycle was then followed by a post-treatment evaluation that lasted four weeks. The main goals of the trial are safety, tolerability and efficiency of the drug when being used to treat moderate-to-severe papulopustular rosacea.

The results will be revealed during a conference call on Sept. 12 at 9 a.m. EST. There will also be a webcast, which is available at http://public.viavid.com/index.php?id=121064.